Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists
ZNTL

ZNTL - Zentalis Pharmaceuticals Inc Stock Price, Fair Value and News

$2.72-0.03 (-1.09%)
Market Closed

Price Targets

ZNTL Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

ZNTL Price Action

Last 7 days

18.3%

Last 30 days

11.9%

Last 90 days

94.3%

Trailing 12 Months

50.3%

ZNTL RSI Chart

ZNTL Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

ZNTL Valuation

Market Cap

196.5M

Price/Earnings (Trailing)

-1.32

Price/Sales (Trailing)

3.15

EV/EBITDA

-1.06

Price/Free Cashflow

-1.47

ZNTL Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

ZNTL Fundamentals

ZNTL Revenue

Revenue (TTM)

67.4M

ZNTL Earnings

Earnings (TTM)

-149.3M

Earnings Growth (Yr)

33.54%

Earnings Growth (Qtr)

0.68%

ZNTL Profitability

EBT Margin

-221.76%

Return on Equity

-59.05%

Return on Assets

-45.63%

Free Cashflow Yield

-68.19%

ZNTL Investor Care

Shares Dilution (1Y)

1.38%

Diluted EPS (TTM)

-2.08

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
202400067.4M
20180000
Get all data in R, Python etc through our Historical Stock Data APIs

About Zentalis Pharmaceuticals Inc

ZNTL
Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase, which is in Phase 2 clinical trial for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer. The company's products pipeline also includes ZN-d5, an oral small molecule inhibitor of B-cell lymphoma 2, for hematological malignancies and related disorders; and BCL-xL heterobifunctional degrader, a member of the anti-apoptotic BCL-2 proteins, for solid tumors and hematological malignancies. Zentalis Pharmaceuticals, Inc. has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC; Pfizer, Inc.; Zentera Therapeutics: and GlaxoSmithKline plc. The company was incorporated in 2014 and is headquartered in New York, New York.
 CEO
 WEBSITEhttps://zentalis.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES156

Zentalis Pharmaceuticals Inc Frequently Asked Questions

ZNTL is the stock ticker symbol of Zentalis Pharmaceuticals Inc. Every public company that trades on a stock exchange gets a ticker symbol.

As of Fri Mar 13 2026, market cap of Zentalis Pharmaceuticals Inc is 196.52 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

As of Fri Mar 13 2026, ZNTL's PE ratio (Price to Earnings) is -1.32 and Price to Sales (PS) ratio is 3.15. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ZNTL PE ratio will change depending on the future growth rate expectations of investors.